Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

0
Player Avatar portefeuille (99.75) Submitted: 11/25/2010 2:19:21 PM : Outperform Start Price: $5.39 PGNX Score: +4.05

currently 100 shares in my portfolio.

Report this Post 1 Comment
Member Avatar portefeuille (99.75) Submitted: 1/22/2011 6:04:52 PM
Recs: 0

I no longer update my portfolio positions.

Featured Broker Partners


Advertisement